Radoslaw Kitel (Radosław Kitel)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 13

Top Topics

Network Analysis

Magnetic Resonance

Top Venues

Molecules (Basel, Switzerland)

Expert opinion on therapeutic patents

ACS medicinal chemistry letters

Journal of medicinal chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Aleksandra Hec-Gałązka, Urszula Tyrcha, Jan Barczyński, Przemyslaw Bielski, Michał Mikitiuk, Ganna P Gudz, Radoslaw Kitel, Bogdan M Musielak, Jacek Plewka, Tomasz Sitar, Tad A Holak
Nonsymmetrically Substituted 1,1'-Biphenyl-Based Small Molecule Inhibitors of the PD-1/PD-L1 Interaction. ACS medicinal chemistry letters 15 (6) (2024)
Atilio Reyes Romero, Katarzyna Kubica, Radoslaw Kitel, Ismael Rodriguez, Katarzyna Magiera-Mularz, Alexander Dömling, Tad A Holak, Ewa Surmiak
Correction: Reyes Romero et al. Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules 2022, 27 , 8282. Molecules (Basel, Switzerland) 29 (12) (2024)
Wiktor Uzar, Beata Kaminska, Hubert Rybka, Łukasz Skalniak, Katarzyna Magiera-Mularz, Radoslaw Kitel
An updated patent review on PD-1/PD-L1 antagonists (2022-present). Expert opinion on therapeutic patents 34 (8) (2024)
Aleksandra Hec-Gałązka, Urszula Tyrcha, Jan Barczyński, Przemyslaw Bielski, Michał Mikitiuk, Ganna P Gudz, Radoslaw Kitel, Bogdan M Musielak, Jacek Plewka, Tomasz Sitar, Tad A Holak
Nonsymmetrically Substituted 1,1'-Biphenyl-Based Small Molecule Inhibitors of the PD-1/PD-L1 Interaction. ACS medicinal chemistry letters 15 (6) (2024)
Atilio Reyes Romero, Katarzyna Kubica, Radoslaw Kitel, Ismael Rodriguez, Katarzyna Magiera-Mularz, Alexander Dömling, Tad A Holak, Ewa Surmiak
Correction: Reyes Romero et al. Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules 2022, 27 , 8282. Molecules (Basel, Switzerland) 29 (12) (2024)
Wiktor Uzar, Beata Kaminska, Hubert Rybka, Łukasz Skalniak, Katarzyna Magiera-Mularz, Radoslaw Kitel
An updated patent review on PD-1/PD-L1 antagonists (2022-present). Expert opinion on therapeutic patents 34 (8) (2024)
Wiktor Uzar, Beata Kaminska, Hubert Rybka, Łukasz Skalniak, Katarzyna Magiera-Mularz, Radoslaw Kitel
An updated patent review on PD-1/PD-L1 antagonists (2022-present). Expert opinion on therapeutic patents (2024)
Radoslaw Kitel, Ewa Surmiak, Jan Borggräfe, Justyna Kalinowska-Tluscik, Przemyslaw Golik, Miroslawa Czub, Wiktor Uzar, Bogdan M Musielak, Mariusz Madej, Grzegorz M Popowicz, Grzegorz Dubin, Tad A Holak
Discovery of Inhibitory Fragments That Selectively Target Spire2-FMN2 Interaction. Journal of medicinal chemistry (2023)
Atilio Reyes Romero, Katarzyna Kubica, Radoslaw Kitel, Ismael Rodriguez, Katarzyna Magiera-Mularz, Alexander Dömling, Tad A Holak, Ewa Surmiak
Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules (Basel, Switzerland) 27 (23) (2022)
Atilio Reyes Romero, Katarzyna Kubica, Radoslaw Kitel, Ismael Rodriguez, Katarzyna Magiera-Mularz, Alexander Dömling, Tad A Holak, Ewa Surmiak
Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules (Basel, Switzerland) 27 (23) (2022)
Karolina Juszczak, Anna Chmurska, Radoslaw Kitel, Grzegorz Dzido, Magdalena Łabieniec-Watała, Serafin Zawadzki, Agnieszka Marczak, Krzysztof Walczak, Karolina Matczak, Mateusz D Tomczyk
Hexokinase 2 Inhibition and Biological Effects of BNBZ and Its Derivatives: The Influence of the Number and Arrangement of Hydroxyl Groups. International journal of molecular sciences 23 (5) (2022)
Atilio Reyes Romero, Katarzyna Kubica, Radoslaw Kitel, Ismael Rodriguez, Katarzyna Magiera-Mularz, Alexander Dömling, Tad A Holak, Ewa Surmiak
Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules (Basel, Switzerland) 27 (23) (2022)
Atilio Reyes Romero, Katarzyna Kubica, Radoslaw Kitel, Ismael Rodriguez, Katarzyna Magiera-Mularz, Alexander Dömling, Tad A Holak, Ewa Surmiak
Computer- and NMR-Aided Design of Small-Molecule Inhibitors of the Hub1 Protein. Molecules (Basel, Switzerland) 27 (23) (2022)